Skip to main content

Table 1 summarizes the demographic and clinical characteristics of the participants in the study

From: Anxiety and depression in primary Sjögren’s syndrome: a cross-sectional study

Clinical characteristics pSS(n = 160) Controls(n = 170) t/x 2 p
Age, mean ± sd years 51.09 ± 12.11 50.14 ± 11.22 0.32 0.446
Gender, female, no. (%) 152(95) 162(95.3) 0.02 0.901
Marital status, no. (%)    3.50 0.061
 Married 151 (94.4) 167 (98.2)   
 Other marital status 9 (5.6) 3 (1.8)  
Education, years 12.19 ± 4.33 12.03 ± 4.62 0.33 0.740
Employment status, no. (%)    1.28 0.259
 Employed 71(44.4) 86(50.6)   
 Unemployed 89(55.6) 84(49.4)  
Income/person/year, yuan, no. (%)    1.65 0.569
  < 15,000 yuan 55 (34.37) 49(28.8)   
 15,000-33,000 yuan 49 (30.63) 62(36.5)  
  ≥ 33,000 yuan 56(35) 59(34.7)  
Type of medical insurance, n (%)    4.33 0.115
 With basic medical insurance 146(91.3) 164(96.5)   
 Self-pay 13(8.1) 6(3.5)  
 Other 1(0.6) 0(0)  
HADS-A, mean ± sd 6.52 ± 4.06 3.02 ± 2.78 9.08 0.000
HADS-D, mean ± sd 6.71 ± 4.32 3.87 ± 2.80 7.05 0.000
Disease duration, mean ± sd years 4.498 ± 5.44  
OSDI, mean ± sd 29.14 ± 25.12  
VAS pain (range 0–10), mean ± sd 2.36 ± 2.65  
ESR, mean ± sd mm/h 30.65 ± 24.13  
RF positivity, yes, no. (%) 51(49.5)  
Hospitalization, yes, n (%) 108(67.5)  
Family history, yes, n (%) 23(14.4)  
Comorbid conditions, yes, n (%) 102(63.75)  
ESSDAI 9.6 ± 7.3  
ESSPRI 4.53 ± 1.95  
FSS 3.89 ± 1.59 1.64 ± 0.89 15.76 0.000
OHIP-14 12.89 ± 11.38 3.41 ± 4.92 9.29 0.000
MDADI 72.33 ± 18.83  
IgG (g/L) 18.93 ± 6.65  
C3 (g/L) 0.81 ± 0.27  
C4 (g/L) 0.18 ± 0.65  
ANA ≥1: 320 96(91.4)  
Anti-SSA ≥ 200 RU/mL 85(81)  
Anti-SSB ≥ 20 RU/mL 53(50.5)  
  1. VAS visual analog scale, ESR erythrocyte sedimentation rate, RF rheumatoid factor, HADS hospital anxiety and depression scale, HADS-A hospital anxiety scale, HADS-D hospital depression scale, ESSDAI EULAR Sjögren’s syndrome disease activity index, ANA antinuclear antibodies, IgG Immunoglobulin G, C3 complement C3, C4 complement C4, OSDI the ocular surface disease index